CDK4 and breast carcinoma: We have previously shown that the combination of CDK4/6 and glutaminase inhibitors presents strong antiproliferative synergies in colon and breast cancer cells with no significant cytotoxic effects on non-malignant cells [36], predicting this combination as a promising therapeutic option in cancer treatment.